Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, Trinh R, Sulkowski MS. Eron JJ, et al. Among authors: fredrick l. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394009 Free PMC article.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Sulkowski MS, et al. Among authors: fredrick l. JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328. JAMA. 2015. PMID: 25706092 Clinical Trial.
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, Tian M, Fredrick L, Podsadecki T, Norton M, Nilius A. Reynes J, et al. Among authors: fredrick l. AIDS Res Hum Retroviruses. 2013 Feb;29(2):256-65. doi: 10.1089/aid.2011.0275. Epub 2012 Aug 3. AIDS Res Hum Retroviruses. 2013. PMID: 22730929 Clinical Trial.
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM. Reynes J, et al. HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255. HIV Clin Trials. 2011. PMID: 22180523 Clinical Trial.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Rockstroh JK, et al. Among authors: fredrick lm. Open Forum Infect Dis. 2017 Jul 22;4(3):ofx154. doi: 10.1093/ofid/ofx154. eCollection 2017 Summer. Open Forum Infect Dis. 2017. PMID: 28948180 Free PMC article.
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. Gathe J, et al. Among authors: fredrick l. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81. doi: 10.1097/QAI.0b013e31819c2937. J Acquir Immune Defic Syndr. 2009. PMID: 19225400 Clinical Trial.
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
Zajdenverg R, Podsadecki TJ, Badal-Faesen S, Andrade-Villanueva J, Gathe J, Mingrone H, Fredrick LM, Gaultier IA, Woodward WC, Bernstein BM. Zajdenverg R, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):143-51. doi: 10.1097/QAI.0b013e3181cbd21e. J Acquir Immune Defic Syndr. 2010. PMID: 20134330 Clinical Trial.
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, Puoti M, Caruntu F, Slim J, Nevens F, Sigal S, Cohen S, Fredrick LM, Pires Dos Santos AG, Rodrigues L Jr, Dillon JF. Zuckerman E, et al. Among authors: fredrick lm. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2544-2553.e6. doi: 10.1016/j.cgh.2020.06.044. Epub 2020 Jul 1. Clin Gastroenterol Hepatol. 2020. PMID: 32621971 Free article.
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
Grebely J, Dore GJ, Alami NN, Conway B, Dillon JF, Gschwantler M, Felizarta F, Hézode C, Tomasiewicz K, Fredrick LM, Dumas EO, Mensa FJ. Grebely J, et al. Among authors: fredrick lm. Int J Drug Policy. 2019 Apr;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. Epub 2019 Feb 6. Int J Drug Policy. 2019. PMID: 30735896 Free article.
42 results